Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 4/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.77 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.58 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.58 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.54 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SHBG | P04278 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrocortisone SCHEMBL4111245 | 1.00 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL1184193 | 1.00 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL5610354 | 1.00 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL1184192 | 1.00 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL193711 | 1.00 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL5139991 | 0.99 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL8366487 | 0.99 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL8360187 | 0.99 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL11169159 | 0.99 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL6461669 | 0.99 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | THE BROAD INSTITUTE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250376656-A1 | MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-12-11 | — | — | US | disclosed |
| WO-2025068686-A1 | TREATMENT FOR BATTEN DISEASE | THE ROYAL VETERINARY COLLEGE (GB) | 2025-04-03 | — | — | WO | disclosed |
| US-20220228190-A1 | MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-07-21 | — | — | US | disclosed |
| US-9673030-B2 | Computer readable storage mediums, methods and systems for normalizing chemical profiles in biological or medical samples detected by mass spectrometry | EMORY UNIVERSITY (US) | 2017-06-06 | — | — | US | disclosed |
| CN-102731499-B | Lactam compound and the application as medicine thereof | Because of C1-esteraseremmer-N parent corporation (US) | 2016-01-13 | — | — | CN | disclosed |
| CN-104672311-A | Lipopeptides for delivery of nucleic acids | MARINA BIOTECH INC | 2015-06-03 | — | — | CN | disclosed |
| US-20140309186-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION | 2014-10-16 | — | — | US | disclosed |
| CN-102124102-B | Methods for optimizing electroporation | MAXCYTE INC | 2013-12-18 | — | — | CN | disclosed |
| CN-101412742-B | Nitric acid ester medicament for inhibiting angiogenesis | TIANJIN JINYAO GROUP CO LTD | 2013-07-31 | — | — | CN | disclosed |
| CN-101156860-A | Use of mometasone furoate for treating airway passage and lung diseases | SCHERING CORP (US) | 2008-04-09 | — | — | CN | disclosed |
| CN-101103016-A | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same | INCYTE CORP (US) | 2008-01-09 | — | — | CN | disclosed |
| CN-100358528-C | Use of mometasone furoate for preparing medicine | SCHERING CORP (US) | 2008-01-02 | — | — | CN | disclosed |
| CN-101098856-A | Lactam compounds and their use as pharmaceuticals | INCYTE SAN DIEGO INC (US) | 2008-01-02 | — | — | CN | disclosed |
| CN-101001850-A | Amido compounds and their use as pharmaceuticals | INCYTE CORP (US) | 2007-07-18 | — | — | CN | disclosed |
| CN-1531967-A | Use of mometasone furoate for treating airway nassage and lung diseases | ���鹫˾ | 2004-09-29 | — | — | CN | disclosed |
| CN-1342146-A | Substituted 1-oxo-and 1, 3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels | CELGENE CORP (US) | 2002-03-27 | — | — | CN | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| CN-1139384-A | Use of mometasone furoate for treating respiratory and pulmonary diseases | SCHERING CORP (US) | 1997-01-01 | — | — | CN | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | STUB1, SAMM50, CD14 | G6PD 3668/4885CYP3A4 1640/4885GABRA1 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.